Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Estrogen-related receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The ERRs are orphan nuclear receptors, meaning the identity of their endogenous ligand has yet to be unambiguously determined. They are named because of sequence homology with estrogen receptors, but do not appear to bind estrogens or other tested steroid hormones.
SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Compounds as the estrogen related receptors modulators and the uses thereof
InactiveUS20110071148A1Narrow downRestore insulin sensitivityOrganic active ingredientsBiocideFatty liverAcute hyperglycaemia
The compounds according to formula VIII, their pharmaceutically acceptable acid or base addition salts, and the uses thereof is disclosed. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for the preparing a medicament for modulating estrogen related receptor (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity, etc. The definition of the groups of the formula is defined as the description.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Compounds and methods for treating breast cancer and other diseases
Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and / or estrogen related receptors.
Owner:CITY OF HOPE
Compounds and methods for treating breast cancer and other diseases
ActiveUS20050096384A1Efficient and inexpensiveEfficient modulationBiocideOrganic chemistryPhysiologyBiological activation
Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and / or estrogen related receptors.
Owner:CITY OF HOPE
Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use
Disclosed are compositions for treating an estrogen receptor (ER) or estrogen related receptor (ERR) mediated disorder, comprising a therapeutically effective amount of a compound selected from the group consisting of Compound Nos. 1-9, 7-2, 7-4, 7-5, 7-7, 7-8, 8-2 and 3-15 set forth herein or a pharmaceutically acceptable salt thereof, wherein said compound modulates estrogen receptors and / or estrogen-related receptors and methods for use of said compositions.
Owner:CITY OF HOPE
Compound used as estrogen-related receptor regulator and application of compound
ActiveCN104119285AGrowth inhibitionAbility to inhibit migrationMetabolism disorderDigestive systemDiseaseHydrogen-1
The invention discloses a compound used as an estrogen-related receptor regulator and an application of the compound. The compound is a 1-hydrogen-1, 2, 3-triazole compound with a structure as shown in formula (I) as well as pharmaceutical acceptable salt or prodrug molecule. The compound as well as pharmaceutical acceptable salt or prodrug molecule can be used for preparing drugs for adjusting activity of estrogen relevant receptor (ERR), preventing and treating breast cancer (comprising diseases which are free of influence of an anti-estrogen method), prostatic cancer or metabolic diseases. The formula (I) is as shown in the specification.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Compound used as a regulator of estrogen-related receptor and applications thereof
ActiveCN101531638ARestore sensitivityImproves Glucose BalanceOrganic active ingredientsOrganic chemistryAcute hyperglycaemiaFatty liver
Owner:东莞市恩联干细胞生物科技研究院
Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation
InactiveUS20070054859A1Promote cartilage formationInhibit cartilage formationCompound screeningApoptosis detectionDiseaseMammal
Estrogen related receptor α (ERRα) is involved in control of cartilage formation in mammals. Increasing ERRα activity causes stimulation of cartilage formation, providing a means of therapeutic intervention in diseases such as arthritis which involve cartilage destruction. Compounds may be screened for their potential as therapeutics by screening their effect on ERRα cartilage promoting activity.
Owner:AUBIN JANE E +1
Reprogramming progenitor compositions and methods of use therefore
ActiveUS20180044642A1Improve efficiencyGenetically modified cellsSkeletal/connective tissue cellsProgenitorHuman Induced Pluripotent Stem Cells
The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
Owner:RONALD M EVANS AGENT +1
Aminothiazolones as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators
Owner:JANSSEN PHARMA NV
Medical application of encoding gene ESRRA of estrogen-related receptor alpha (ERR alpha)
PendingCN113117097AEasily damagedReduce lipid accumulationPeptide/protein ingredientsDigestive systemAdenoassociated virusBile Juice
The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.
Owner:CHINA PHARM UNIV
Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Estrogen related receptor, ERRalpha, a regulator of bone formation
Methods and pharmaceutical compositions are provided for modulating bone formation in a mammal. Methods are also provided for screening compounds for their efficacy as modulators of bone formation.
Owner:AUBIN JANE +1
Macrobrachium rosenbergii estrogen-related receptor gene ERR and application thereof
ActiveCN105624169AHigh activityConvenient sourceReceptors for hormonesFermentationPerturbateurs endocriniensNucleotide
The invention discloses a macrobrachium rosenbergii estrogen-related receptor gene ERR. The nucleotide sequence of the gene ERR is shown as SEQ ID NO:1, and the amino acid sequence of the gene ERR is shown as SEQ ID NO:2. The invention further discloses application of the recombined macrobrachium rosenbergii estrogen-related receptor gene ERR to environmental internal-secretion interfering-substance detection and pollution assessment, and macrobrachium rosenbergii ERR protein has important application value in the aspects of natural water environment internal-secretion interfering-substance (like NP) detection and pollution assessment.
Owner:海南永贺生物科技有限公司
Use of estrogen-related receptor alpha as diagnostic marker for glioma and related application
InactiveCN107604060APrevent proliferationInhibit migrationMicrobiological testing/measurementBiological testingEstrogen-related receptor alphaGlioma
The present invention discloses use of estrogen-related receptor alpha (ERR alpha) as a diagnostic marker for glioma and related application, also discloses application of the ERR alpha and an activecomponent for down-regulating or blocking of expression of ERR alpha molecule in the glioma in preparation of a related kit and drug for diagnosis and treatment of the glioma, and provides a new method for diagnosis and treatment of the glioma.
Owner:复旦大学附属华山医院北院
Reprogramming progenitor compositions and methods of use therefore
ActiveUS10920199B2Genetically modified cellsSkeletal/connective tissue cellsBiochemistryMultipotential stem cell
Owner:RONALD M EVANS AGENT +1
Uses of estrogen correlated acceptor 2 in maintaining versatility of mouse embryo stem cell
InactiveCN101492677ARich materialRich Regulatory NetworkMicrobiological testing/measurementBiological testingGerm layerMammal
The invention discloses a carrier construction method of a mouse Esrrb (estrogen-related receptor 2) gene and an application thereof in researches on mouse embryonic stem cells. Lack of the Esrrb in the mouse leads to stem cell differentiation of an epiblast and abnormal embryonic development, the embryo dies within ten and half a days during the development, which indicates that the Esrrb plays a very important role in maintaining normal embryonic development of the mammal. In the invention, the Esrrb is taken as a transcription factor which can maintain pluripotent function of the embryonic stem cells without depending on LIF (Leukemia Inhibitory Factor). The construction method of the recombinant of the invention and the application thereof in embryonic stem cells provide reference for studying how other transcription factors play a role in the embryonic stem cells.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus, gene segment capable of reducing drug resistance of laodelphax striatellus and application of gene segment
ActiveCN107266559ADelay drug resistanceAchieving Antimicrobial Resistance GovernanceMicrobiological testing/measurementReceptors for hormonesDrug resistanceEstrogen-related receptor
The invention relates to a drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus, a gene segment capable of reducing drug resistance of laodelphax striatellus and an application of the gene segment. The sequence of the drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus is shown as SEQ ID NO.1. The sequence of the gene segment capable of reducing drug resistance of laodelphax striatellus is shown as SEQ ID NO.3. The gene segment is used for reducing drug resistance of laodelphax striatellus. The gene segment can be used for detecting drug resistance of laodelphax striatellus, and drug resistance management of laodelphax striatellus is realized.
Owner:JIANGSU ACAD OF AGRI SCI
Substituted thiophene compound as well as preparation method and application thereof
ActiveCN112142711AMetabolism disorderGroup 5/15 element organic compoundsDiseasePharmaceutical medicine
The invention relates to a thiophene compound and pharmaceutically acceptable salts thereof represented by a general formula I, a preparation method thereof, a pharmaceutical composition containing the thiophene compound or pharmaceutically acceptable salts thereof, and applications of the thiophene compound and the pharmaceutically acceptable salts. The thiophene compound and the pharmaceuticallyacceptable salts thereof are used as a novel estrogen-related receptor alpha (ERR[alpha]) inverse agonist. The compound can be used to treat diseases associated with ERR and ERR[alpha], such as cancer, osteoporosis, diabetes, aging resistance, weight loss, and the like. After further optimization and screening, the compound is expected to be developed into a novel medicine for preventing and treating tumors or other ERR[alpha] related diseases.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Compounds of estrogen-related receptor modulators and the uses thereof
InactiveUS8853221B2Improve glucose homeostasisRestore sensitivityBiocideOrganic active ingredientsFatty liverPharmaceutical medicine
The compounds according to formula (VIII), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity. The substituents of the formula are defined in the description.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators
The present invention relates to compounds of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Compounds of estrogen-related receptor modulators and the uses thereof
InactiveUS20110218196A1Narrow downRestore insulin sensitivityOrganic active ingredientsBiocideFatty liverPharmaceutical medicine
The compounds according to formula (VIII), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity. The substituents of the formula are defined in the description.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
A kind of 4-bromophenylurea compound that regulates the activity of estrogen-related receptors and its medical application
The invention discloses a novel 4-bromophenylurea compound with formula I for regulating estrogen-related receptor activity, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
A novel n-p-tolyl-benzamide compound that regulates the activity of estrogen-related receptors and its medical application
The invention discloses a novel N-p-tolyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
Novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound and medical uses thereof
The present invention discloses a novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound having a structure represented by a formula I, a pharmaceutically acceptable salt and applications thereof, wherein the compound and the pharmaceutically acceptable salt thereof can be used for preparation of drugs for regulating the activity of estrogen-related receptors ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha) and preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. The formula I is defined in the specification.
Owner:QILU UNIV OF TECH
Novel 3-bromophenyl urea estrogen-related receptor activity regulation compound and medical use thereof
The invention discloses a novel 3-bromophenyl urea estrogen-related receptor activity regulation compound, its pharmaceutically acceptable salt and application thereof. The compound and its pharmaceutically acceptable salts can be used for preparation of drugs capable of regulating estrogen related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) activity, preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. (formula I).
Owner:QILU UNIV OF TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com